• Safe in PET: COVAP’s first complete aseptic PET line from Sidel

    Thanks to Sidel’s end-to-end complete aseptic PET line, UHT liquid dairy products (LDPs) from Spanish milk producer COVAP are now also available in PET bottles for the very first time. This new PET bottle opens the door to meet changing market demand and ensures product integrity and safety.

  • LINHARDT GOES CANNABIS

    LINHARDT’s mission is to provide “packaging for your life”. As cannabis products increasingly become a part of many peoples' lives, we’ve spent the last year developing a range of secure and high-quality cannabis packaging solutions.

    We’re excited to announce, that for the first time ever, LINHARDT exhibits at CannaCon Midwest 2021 Chicago, on August 6th - 7th.

    We’d like to invite all of you, to pay a visit to our stand 106, where we will introduce our latest products and innovations for cannabis packaging.

    The last year has been challenging in many ways, so we are thrilled to finally meet again in person. Of course, we still have strict health and safety measures in place.

    WHAT TO EXPECT

    CHILD-RESISTANT CANNABIS PACKAGING

    RIGID TUBE WITH RESEALABLE SNAP-ON STOPPER* 

    for dry goods and edibles 
    *CRC certificate pending for some diameters

     

    RIGID TUBE WITH PRY-OFF CROWN CAP 

    for liquids and dry goods 

     

     

    TINY-B BOTTLE

    for liquids,
    available soon

     


    NON-CHILD-RESISTANT CANNABIS PACKAGING

    BOTTLES

    Coming Soon 

     

     

     

     

     

    ­ SCREW CANS & SHAKER CANS

     

     

     

     

    CIGAR-STYLE TUBES

     

     

     

     

     

    We would be happy to welcome you to our stand at CannaCon Chicago. If you are not able to attend, you can still take a look at our new cannabis website. LINHARDT CANNABIS

  • At Pack Expo Las Vegas, Antares Vision Group to Demo New Mini Manual Aggregation Station for Small- to Mid-Sized Production, Among Other Recently Introduced Traceability & Inspection Solutions

    Company also will demo “Track My Way,” a traceability platform opening dialogue between various supply chain stakeholders, including consumers. 

  • Cardboard Carriers Deliver for Oslo Brewery

    The new WaveGrip Cardboard Carrier from Berry Global has been selected by Oslo-based Amundsen Brewery, the second largest craft brewery in Norway and one of the fastest growing in the country, to provide a ring carrier solution for its range of beer cans.

  • SÜDPACK is committed to a sustainable packaging indus-try

    Approximately 65 editors and business journalists registered and logged in to the first virtual SÜDPACK press conference on 7 July 2021. The film manufacturer deliberately chose the digital format in order to provide both the national and international press with comprehensive information about “Sustainability at SÜDPACK” even during the corona pandemic. The first virtual SÜDPACK exhibition also launched at the same time and its digital doors are now open to customers and interested parties around the clock, 365 days a year.

  • Fresenius Kabi Introduces New Simplist® Fentanyl Citrate Injection, USP 50 mcg per 1 mL in Ready-to-Administer Prefilled Syringe

    News: 

    Simplist® Fentanyl ready-to-administer prefilled syringes come in Fresenius Kabi’s proprietary MicroVault® packaging system that also supports secure dispensing of narcotics and reduces the opportunity for diversion. Because the syringes require no assembly, they streamline point-of-care preparation. The presentation reduces the potential for product waste and makes it easier for health care professionals to dispense the prescribed dose.

    Fresenius Kabi is a leader in injectable medicines with a growing U.S. portfolio of prefilled syringes.

    “The introduction of an exclusive smaller-dose fentanyl injection is an important expansion of our Simplist® ready-to-administer prefilled syringe portfolio in line with our commitment to the secure dispensing of controlled substances for the safe delivery of drugs to patients,” said John Ducker, president and CEO of Fresenius Kabi USA. “We are proud to design, develop and introduce products and labeling that support the safe dispensing of controlled substances, and all products.”

    About Simplist® Fentanyl MicroVault® Prefilled Syringe

    Fresenius Kabi’s Simplist® prefilled syringes were associated with an error rate that was four times lower when compared to traditional medication administration practice, according to a study published in the Journal of Patient Safety in 2018. The Simplist Fentanyl prefilled syringe is manufacturer prepared in the United States, with a 24-month shelf life, and is a single-unit dose, supporting best practices for medication administration.

    Fentanyl Citrate Injection, for intravenous or intramuscular use, is indicated for:

    • Analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance and in the immediate postoperative period (recovery room) as the need arises.
    • Use as an opioid analgesic supplement in general or regional anesthesia.
    • Administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia.
    • Use as an anesthetic agent with oxygen in selected high-risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures.

    Fentanyl Citrate Injection should be administered only by persons specifically trained in the use of intravenous anesthetics and management of the respiratory effects of potent opioids. Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available.

  • PLUSS, Apollo LogiSolutions set up packaging boxes facility for temperature sensitive vaccines

    News: 

    PLUSS Advanced Technologies (PLUSS), a Delhi based company, in collaboration with Apollo Supply Chain, part of the Apollo International Group, has set up a 20,000 sqft facility in Hyderabad, for packaging boxes for temperature sensitive vaccines, pharmaceuticals and biologics.

    The boxes maintain inside temperature without electricity at desired levels for over 4 days, using ‘phase change materials’ technology. The facility has the capacity to condition boxes for transporting the equivalent of 3 to 5 million vaccine doses per month and will cater to the various vaccine and pharma manufacturers in and around Hyderabad.

    Samit Jain, CEO, PLUSS, said, “With the installation of this facility, the burden of creating a cold chain logistics infrastructure for pharmaceutical companies can be reduced. Shared resources always make a lot of sense, in the long run, it reduces costs and expenses for everyone in the endeavour to increase access to temperature-sensitive healthcare products. The boxes come pre-fitted with temperature sensors and monitoring of temperature is seamless.”

    Raaja Kanwar, VC & MD, Apollo LogiSolutions, said, “This facility addresses the obligation on pharmaceutical companies to create a cold-chain supply infrastructure for the vaccines.”

    The temperature-sensitive boxes, called Celsure boxes, are customizable and can maintain temperature from -70 to +30 degree Celsius, in 35 different ranges. The boxes are also used to transport Covid-19 vaccines, which require temperatures in the range +15 to +25, -15 to -25, and +2 to +8 degree Celsius. The Celsure box serves as a better and safer alternative to dry ice and conventional ice-packs, and brings about operational and cost efficiency in transporting temperature-sensitive cargo, including pharmaceutical products, vaccines and foodstuff.

    PLUSS has partnered with pharmaceutical companies across India for transporting their products using Celsure boxes and also exports Celsure boxes and its ‘phase change materials’ to pharma packaging suppliers in Europe and the USA. PLUSS has received a patent for the Celsure box from the United States Patent and Trademark Office and the European Patent Office in Germany and has applied for a patent in India, Singapore and Brazil.

  • PLUSS, Apollo LogiSolutions set up facility in HYD for temp-control vaccine boxes

    News: 

    The boxes maintain inside temperature without electricity at desired levels for over 4 days, using ‘phase change materials’ technology. The facility has the capacity to condition boxes for transporting the equivalent of 3 to 5 million vaccine doses per month and will cater to the various vaccine and pharma manufacturers in and around Hyderabad.

    Samit Jain, CEO, PLUSS, said, “With the installation of this facility, the burden of creating a cold chain logistics infrastructure for pharmaceutical companies can be reduced. Shared resources always make a lot of sense, in the long run, it reduces costs and expenses for everyone in the endeavour to increase access to temperature-sensitive healthcare products. The boxes come pre-fitted with temperature sensors and monitoring of temperature is seamless.”

    Raaja Kanwar, VC & MD, Apollo LogiSolutions, said, “This facility addresses the obligation on pharmaceutical companies to create a cold-chain supply infrastructure for the vaccines.”

    The temperature-sensitive boxes, called Celsure boxes, are customizable and can maintain temperature from -70 to +30 degree Celsius, in 35 different ranges. The boxes are also used to transport Covid-19 vaccines, which require temperatures in the range +15 to +25, -15 to -25, and +2 to +8 degree Celsius. The Celsure box serves as a better and safer alternative to dry ice and conventional ice-packs, and brings about operational and cost efficiency in transporting temperature-sensitive cargo, including pharmaceutical products, vaccines and foodstuff.

    PLUSS has partnered with pharmaceutical companies across India for transporting their products using Celsure boxes and also exports Celsure boxes and its ‘phase change materials’ to pharma packaging suppliers in Europe and the USA. PLUSS has received a patent for the Celsure box from the United States Patent and Trademark Office and the European Patent Office in Germany and has applied for a patent in India, Singapore and Brazil.

  • Packaging Fillers: The Unsung Heroes Of Packaging

    An integral part of packaging design, especially in this era of ecommerce and abundant international shipments of fragile products, packaging fillers need to chosen correctly if you want your packaging to serve its purpose.

  • Nerlynx Labeling Updated to Include Dose Escalation and New Packaging

    News: 

    Nerlynx is a kinase inhibitor indicated as a single agent for the extended adjuvant treatment of adults with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy. It is also indicated in combination with capecitabine for the treatment of adults with advanced or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 based regimens in the metastatic setting.

    The approval for the use of Nerlynx dose escalation was based on data from the multicenter, open-label, multi-cohort phase 2 CONTROL trial (ClinicalTrials.gov Identifier: NCT02400476) that included adults with early stage HER2-positive breast cancer. Patients received either Nerlynx 240mg daily for up to 1 year, along with loperamide prophylaxis with additional anti-diarrheal treatment as needed, or Nerlynx dose escalation with loperamide as needed. In the dose escalation cohort, patients received Nerlynx 120mg daily for week 1, then 160mg daily for week 2, then 240mg daily for week 3 and thereafter.

    Findings showed that dose escalation therapy was associated with improved management and prevention of grade 3 diarrhea, including a 60% reduction in the percentage of patients with grade 3 diarrhea (40% vs 13%), a 50% reduction in median cumulative days of grade 3 diarrhea (5 days vs 2.5 days), and an approximately 80% reduction in discontinuation rates (17% vs 3%), when compared with data from the phase 3 ExteNET trial (ClinicalTrials.gov Identifier: NCT00878709), which did not include dose escalation or antidiarrheal prophylaxis.

    “We believe that utilizing dose escalation has the potential to improve the overall tolerability of Nerlynx and increase the average length of therapy, with the end result benefiting more patients battling breast cancer,” said Alan H. Auerbach, Chief Executive Officer and President of Puma.

    Nerlynx will also be made available in a new 133-count bottle containing a 4-week supply of 40mg tablets for use in dose escalation.

  • Pages